NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

Thanx for this.
Here is a quote from this paper:

Cellular vaccines are a viable option for glioma immunotherapy. The dendritic cell vaccine (DCV) is composed of dendritic cells loaded with tumor antigens capable of provoking immune responses. The relative safety and potential efficacy of DC-based vaccinations have been observed in phase I/II clinical trials19. A completed large phase III non-randomized controlled trial in 331 GBM patients has demonstrated the feasibility and potency of tumor lysate-loaded DCV (DCVax-L)20. The study has established the safety profile and demonstrated a survival benefit of the combination therapy, on the basis of an OS surpassing that of patients receiving the standard of care (SOC). Patients receiving the combined therapy exhibited a prolonged median OS (22.3 months after surgery in patients with newly diagnosed GBM and 13.2 months after relapse in patients with recurrent GBM); therefore, DCVax-L has substantial potential in the treatment in GBM.